ArticleFrontiers in pharmacology2026
Integrated proteomic and metabolomic analysis reveals the mechanism of astragalus complanatus flavonoids against liver fibrosis in rats.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Astragali Complanati Semen (ACS) is a traditional Chinese medicinal herb conventionally applied to tonify the liver and kidney. As the primary bioactive ingredients of ACS, Astragalus complanatus flavonoids (ACF) exert hepatoprotective and anti-fibrotic effects. This study aimed to elucidate the antifibrotic mechanisms of ACF through integrated proteomic and metabolomic analyses combined with experimental validation. Methods: A CCl Results: Compared with the LF model group, ACF treatment significantly ameliorated liver function indicators, relieved histopathological injury and collagen deposition, decreased serum fibrosis markers, downregulated the protein levels of Col I, Col IV and α-SMA, and reduced oxidative stress and inflammatory response. Proteomic screening uncovered 401 differentially expressed proteins (DEPs), which were primarily enriched in extracellular matrix (ECM)-receptor interaction, focal adhesion and PI3K/AKT signaling pathways. Protein-protein interaction analysis further pinpointed FN1, CD44, ITGAV, FAK and AKT1 as core target proteins. In vitro experiments demonstrated that ACF blocked TGF-β1-triggered HSC activation, lowered the expression of α-SMA and ITGAV, and inhibited the phosphorylation of FAK and AKT. Pharmacological blockade of either FAK with PF-562271 or AKT with MK2206 strengthened the anti fibrogenic activity of ACF, verifying that the FAK/ AKT axis mediates the anti-HSC activation effect of ACF. Metabolomic analysis identified 108 differentially expressed metabolites (DMs), mainly enriched in glutathione metabolism, primary bile acid biosynthesis and carbohydrate metabolism. Integrated multi-omics analysis confirmed close correlations between DEPs and DMs within ECM-receptor interaction, PI3K/AKT signaling and primary bile acid biosynthesis pathways. Specifically, glycochenodeoxycholic acid, dulcitol and chenodeoxycholate showed strong correlations with coretarget proteins. Conclusion: ACF achieves comprehensive anti-LF effects via suppressing FAK/AKT1 signaling to restrain HSC activation, while coordinately modulating pivotal metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.